Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054555 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
A Phase 3 study of Melanoma, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 633
- Enrollment target
- 20
- Study locations
NCT06054555: Active Phase 3 study of Melanoma, sponsored by Amgen.
NCT06054555 is a Phase 3 study of Melanoma that is active but no longer recruiting, run by Amgen. The registered enrollment target is 633 participants, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06054555, a Phase 3 study of Melanoma, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 633 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG ABP 206
Study Locations (20)
Río Negro Province
- Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology - Mar Del Plata
- Clínica Viedma - Oncology - Viedma
California
- Cancer and Blood Specialty clinic - Long Beach
Indiana
- Fort Wayne Medical Oncology and Hematology - Office of Clinical Research - Fort Wayne
Louisiana
- Our Lady of the Lake Physicians Group-Medical Oncology-Woman's Pavilion - Baton Rouge
Missouri
- Oncology Hematology Associates - Springfield
New York
- Hematology-Oncology Associates of Central New York, P.C. (HOA) - East Syracuse - CCOP - East Syracuse
Ciudad Autónoma de Buenos Aire
- Centro de Investigaciones Médicas y Desarrollo LC - Buenos Aires
Santa Fe Province
- Instituto De Oncologia De Rosario - Rosario
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 633 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2028-01-25 |
| Phase | Phase 3 |
What the registry record for NCT06054555 still lists
NCT06054555 is an interventional study that assigns participants to a tested intervention. The registered 633 participants enrollment target is mid-sized for trials with a published cap, below the 704-participant average among 266 other Melanoma trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT06054555 names 20 study sites across 19 states, led by Río Negro Province, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06054555 about?
NCT06054555 is a clinical study titled "A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma". The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
What is the current status of trial NCT06054555?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 633 participants. The study started on 2023-11-02. Estimated completion is 2028-01-25.
What conditions does trial NCT06054555 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT06054555?
The interventions under investigation include: Nivolumab (DRUG), ABP 206 (DRUG).
Who is sponsoring clinical trial NCT06054555?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054555 being conducted?
This trial has 20 study locations across California, Indiana, Louisiana, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06054555's enrollment target sits among peer trials
633 33rd of 266 higher than 234 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- NCT07237295 · 634 participants · NA
CommunityRx-Kidney Health
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI